Pfizer dumps a failed PhII Huntington’s drug in latest pipeline pruning
Pfizer used one of its footnotes in the Q1 report to sweep out an experimental Huntington’s drug that failed recently in a Phase II trial, the latest in a long series of implosions in the neuroscience field.
Pfizer didn’t explain what went wrong for PF-02545920, but in a blog post at HDBuzz in December, which was edited by one of the investigators in the study, the drug was written off as a complete flop in improving the ability of patients to function better — or boost scores on any other symptoms evaluated in the 271-patient trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.